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Abstract
Background: Intestinal differentiation of primary mucinous adenocarcinoma of the uterine corpus is exceedingly rare
in comparison to the approximately 25% rate in endocervical and ovarian mucinous carcinoma. Additionally, little is
known about the related genetic and epigenetic alterations, even though large-scale molecular characterisation of
the different types of endometrial cancer took place in the TCGA project along the entities defined by the recent
WHO classification.
Case presentation: We present a 62-year-old patient harbouring a primary mucinous carcinoma of the uterine corpus
with a morphological resemblance to mucinous colorectal adenocarcinoma. The intestinal differentiation was substantiated
by CDX2 and CK20 positivity in the absence of PAX8, p16, WT1, p53, ER, PgR, AFP, SALL4 and Glypican3. A high MSI status
with MLH1 hypermethylation was revealed by molecular testing.
Conclusion: Intestinal differentiation of mucinous adenocarcinoma of the endometrium is a unique observation.
Besides morphology, it obviously can share molecular features of sporadic MSI colorectal cancers. It can be speculated
that either CDX2 positive morula formation or intestinal metaplasia of the endometrium as rare conditions might be
the origin of carcinogenesis for this type II endometrial cancer. Both conditions were not detectable in this case. Of
note, categorising endometrial cancers in genetic subgroups like MSI high cancers alone might lead to the integration
of likewise morphologically different tumours like the case presented here with intestinal differentiation. Hence, careful
genotype-phenotype correlations are warranted for studies of mucinous adenocarcinoma of the endometrium.
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Background
Intestinal differentiation occurring in endometrial
carcinoma is rare. This phenomenon was first described
by Berger et al. in 1984 [1] and was confirmed by several
case reports [2–5], but it has not undergone implemen-
tation into the WHO classification of tumours of the
uterine corpus.
According to this morphology-based taxonomy [6],
there are eight accepted types of endometrial carcinoma,
as follows: endometrioid carcinoma, mucinous carcinoma,
serous carcinoma, clear cell carcinoma, mixed cell
adenocarcinoma, undifferentiated carcinoma, dedifferen-
tiated carcinoma and neuroendocrine tumours, with a
spectrum reaching from low-grade neuroendocrine
tumours up to large and small cell high-grade neuroendo-
crine carcinomas, similar to what has been conceptualised
in other organs [7]. The three subtypes in the group of
endometrioid carcinomas include cancers with squamous
differentiation, as well as villoglandular and secretory
carcinomas.
Intestinal differentiation in endometrial cancers has
been shown to be exceedingly less common than in
ovarian or endocervical cancers [8]. Meanwhile, attempts
have been made to learn more from endometrial cancer
by investigating the genetic background. The Cancer
Genome Atlas Research Network (TCGA) recently
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postulated a classification according to genomic features
into four categories, which are the following: polymerase
ε (POLE) ultramutated, microsatellite instability hyper-
mutated, copy-number low and copy-number high [9].
However, the analysis was mostly restricted to classical
endometrioid adenocarcinomas and to a lesser extent to
serous carcinomas of the endometrium. Other subtypes
have been sofar excluded [9].
The microsatellite instable hypermutated tumours are
either associated with Lynch syndrome bearing a germline
mutation in one of the mismatch repair proteins (MLH1,
MSH2, MSH6 and PMS2) or tumours characterised by
sporadic hypermethylation of the MLH1 promotor with
subsequent blockade of the transcription process and loss
of protein expression [6, 10].
However, the correlation between the phenotype and
genotype of endometrial cancers is difficult, and there
are some very rare subtypes of endometrial carcinoma
that are not well represented by these classifications.
We present herein a case of a mucinous adenocarcin-
oma of the endometrium with morphological and molecu-
lar features that resemble an MSI-high adenocarcinoma of
the colon.
Case presentation
Clinical history
A 62-year-old woman, mother of one child from two
pregnancies, presented to our hospital with recent post-
menopausal bleeding. She disclosed no intake of hormo-
nal therapy.
The past medical history was unremarkable with an
appendectomy in her adolescence, menarche at the age
of 12 and menopause starting around the age of 52. Her
body mass index was 21.5. The family history presented
two cousins with breast cancer at 45 years old and an
unknown gynaecological cancer, respectively. In the first
degree family members, no relevant disease was present.
Initial diagnostics consisted of a preoperative endomet-
rial biopsy and an abdominal CT scan. The latter revealed
a mass with clear enlargement of the corpus uteri with
serometra, suspicion of infiltrative growth into adjacent
organs and no evidence of lymph node or distant metas-
tases (Fig. 1a).
A total laparoscopic hysterectomy, bilateral salpingo-
oophorectomy and radical pelvic lymph node dissection
was performed. During surgery, extensive exploration of
the abdominal organs took place (Fig. 1b).
The post-surgical course was uneventful and the
patient was discharged on post-operative day 5. There
was no evidence of a gastrointestinal tumour in subse-
quent gastroscopy, colonoscopy and colposcopy.
Based on the initially completed surgical treatment, no
adjuvant treatment was recommended at the interdiscip-
linary tumour board in accordance with the current
guidelines.
Sixteen months after the initial diagnosis, the patient
presented herself with back pain and 10 kg of weight loss.
A CT scan was performed, which revealed recurrent dis-
ease in the pelvis; peritoneal carcinosis was diagnosed.
Again, no gastrointestinal primary tumour was evident.
The patient refused further diagnostics such as biopsy as
well as palliative chemotherapy. She deceased 21 months
after initial diagnosis under best supportive care in a
palliative care unit.
Methods
Sections (3 μm thick) were deparaffinised and processed
according to routine protocols; details are provided in
Table 1. Molecular MSI testing and MLH1 promotor
methylation analysis followed standard protocols for
Lynch syndrome testing, as published previously [11]
with only slight modifications. DNA was extracted using
the EZ1 tissue kit and the BioRobot EZ1 workstation
(Qiagen, Hilden, Germany). HPV specific PCR was per-
formed according to routine protocols. Six microsatellite
markers were assessed as recommended (BAT25,
BAT26, D2S123, D17S250, D5S346 and BAT40), and
MLH1 methylation status was quantified after bisulfite
treatment and corresponding pyrosequencing (bisulfite
and pyrosequencing kits, Qiagen, Hilden, Germany).
Fig. 1 Radiological and intra-operative findings: a CT radiography showed a serometra with a polypoid exophytic tumour mass with irregular borders
with adjacent organs; b the situs during surgical laparoscopy with enlargement of the uterine fundus, inconspicuous serosal surface and ovaries
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Gross features
Macroscopically, the uterus showed a 4.0 × 3.5 × 2.0 cm
tumour in the fundus with a glassy mucinous cut sur-
face, with infiltration into the inner half of the myome-
trium and no extension into the lower uterine segment
and cervix. The ovaries and fallopian tubes were
unremarkable.
Microscopic features
Histologically, the tumour was confined to the uterine
cavity. No other neoplasias were present in both ovaries,
tubes and the cervix – including no evidence for prema-
lignancies (CIN, AIS). This uterine tumour presented as
mucinous adenocarcinoma limited to the inner half of
the myometrium with infiltrating borders and lymphatic
vessel invasion (Fig. 2 a, b).
The tumour consisted predominantly of highly aty-
pical epithelial cells with a predominantly solid and
cribriform growth pattern with abundant extracellular
mucin. Applying the regular endometrial grading
system, the tumour would have been judged as mo-
derately differentiated (G2), but grading was not fi-
nally confirmed due to the intestinal differentiation.
Intra-tumoural lymphocytes were slightly increased.
Presumably due to tumoural overgrowth we neither
found endometrial intraepithelial neoplasi nor intes-
tinal metaplasia nor morula formation as putative
precursor lesions.
We observed invasion of small lymphatic vessels, but
no evidence of blood vessel invasion nor lymph node or
distant metastases. The final staging was defined as:
pT1a pN0(0/32) L1 V0 Pn0 Gx R0, FIGO IA.
Immunohistochemistry
Immunophenotypically (Fig. 2 c-f ), the tumour was posi-
tive for CDX2 in clusters of up to 60% of tumour cells
with partial expression of cytokeratin 7 and cytokeratin
20 in parallel. Cells were negative for PAX8, WT1,
synaptophysin, chromogranin and vimentin, as well as
for oestrogen and progesterone hormone receptors.
Only scattered cells were positive in p16 staining. Yolk
sac tumour antigens like AFP, SALL4 and Glypican3
were negative. Interestingly, we observed a complete loss
of the mismatch repair proteins MLH1 and PMS2 with
retained nuclear expression of MSH2 and MSH6.
Molecular pathology
According to the molecular analysis, all gene loci of the
tumour cells showed a high grade of microsatellite
instability and strong hypermethylation of the MLH1 pro-
motor. Additionally, no HPV related DNA was detectable
in the tumour.
Discussion
In the female genital tract, mucinous carcinoma can
arise in the vagina, cervix, ovaries and endometrium.
Intestinal differentiation seems to be quite common,
especially in mucinous adenocarcinomas of the cervix
and ovary, with rates up to 25% [8]. This does not ac-
count for mucinous carcinoma of the endometrium. The
morphological and immunohistochemical evidence for
intestinal differentiation in endometrial cancer has only
reached the level of single cases [1–3, 5, 8, 12].
The current case of a postmenopausal woman with a
hormone receptor negative tumour falls within the
spectrum of the clinically relevant group of type II endo-
metrial cancers. In general, carcinogenesis models with
the definition of premalignant conditions for type II endo-
metrial cancers (e.g. serous or clear-cell carcinomas) are
still being investigated, whereas type I endometrial cancers
are believed to evolve stepwise via endometrial intrae-
pithelial neoplasia [6]. Even though this special case of an
endometrial type II cancer is extremely rare, it could be
correlated to a putative metaplasia-carcinoma sequence.
Hence, intestinal metaplasia of the endometrium has been
reported as a rare condition and has been regarded as a
possible source of malignant transformation [4, 13]. It
remains unclear whether milieu factors, inflammation or
infections like those known in the upper gastro-intestinal
tract [14, 15] might trigger in the endometrium the
aberrant expression of CDX2 and the downregulation of
hormone receptors and PAX8 as Müllerian markers, but
these lesions can be discussed as possible precursors of in-
testinally differentiated adenocarcinomas of the uterine
corpus. Unfortunately, the tumour size and overgrowth
masked any putative precursor lesions in the present case.
Table 1 Antibodies used for immunohistochemistry
Target Clone Company Dilution Incubation
CDX2 EPR2764Y CellMarque 1:400 15 min
CK20 Ks 20.8 CellMarque 1:800 15 min
CK7 OV-TL 12/30 CellMarque 1.800 15 min
Oestrogen EP1 DAKO 1:50 30 min
MLH1 ES05 Novocastra 1:200 15 min
MSH2 G219-1129 CellMarque 1:500 15 min
MSH6 PU29 Novocastra 1:100 15 min
p16 E6H4 Ventana 1:5 15 min
Pax8 polyclonal Proteintech 1:200 15 min
PMS2 A16-4 BD Pharmingen 1:100 15 min
Progesterone 16+ SAN27 Novocastra 1:1600 30 min
WT1 6 F-H2 CellMarque 1:100 15 min
AFP polyclonal DAKO 1:1600 15 min
SALL4 6E3 Biocare Medical 1:400 15 min
Gypican 3 1G12 CellMarque 1:200 30 min
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The differential diagnosis of this case included the
already mentioned mucinous adenocarcinomas of other
regions of the female genital tract. An extension from a
cervical cancer could be excluded as well as spread from
the ovaries, as both organ types were completely free of
tumours and metaplastic changes. Additionally, the im-
munohistochemical and molecular profile excludes an
HPV association (negativity for p16 and HPV-DNA,
Additional file 1: Figure S1) or minour serous carcinoma
elements (WT1 negativity and p53 mixed expression).
CDX2 positivity was strong and homogenous and not
confined to substructures like the reported CDX2
positive morules in conventional endometrioid adeno-
carcinoma [16]. Nonetheless, this not well-understood
phenomenon could be a second putative mechanism of
intestinal transdifferentiation in endometrial cancers, but
seems to be less likely as no squamoid elements or
morules were present.
As further differential diagnosis yolk sac tumour of the
endometrium as a very rare condition could be men-
tioned. These tumours can aberrantly express CDX2 and
form a glandular pattern [17]. In rare case reports of
extra-gonadal localization in the uterus, they are
described in premenopausal patients and might cause a
clear cell pattern with resemblance of clear cell adeno-
carcinoma of the endometrium [18, 19]. As a hallmark
they express immunohistochemically AFP, SALL4 and
Glypican3 [17]. All these three markers were negative in
our tumour (Additional file 1: Figure S1) and no morpho-
logical criteria of yolk sac tumour like Schiller-Duval bod-
ies were present. Regarding the age of our patient, the
possibility of yolk sac tumour seems to be implausible
[20]. Nevertheless, some authors argue for the existence
of yolk sac tumour of the endometrium in post-
menopausal patients based on AFP expression [17, 21].
However, it has been shown that gastric and colorectal
cancers can express AFP as well, which can be used as
serological biomarker [22, 23]. Our case report points
towards a simply intestinal differentiated adenocarcinoma
of the uterus. As the yolk sac serves as embryological
ancestor of gastrointestinal organs, there might be an im-
munohistochemical overlap. Possibly, genetics like the loss
Fig. 2 Microscopic findings: H&E sections at low (40×, a) and high (200×, b) magnification showed mucinous differentiation with major elements
of solid and cribriform growth patterns. The immunohistochemical phenotype was characterised by positivity for CDX2 (c), and negativity for
PAX8 (d). Correspondingly, the expression of CK20 (e) followed the CDX2 postive areas. However, CK7 (f) was also present. MLH1 staining (g)
showed a protein loss, whereas MSH2 remained positive (h). Of note, stromal cells served as positive internal controls for MLH1 and MSH2 (g, h)
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of chromosomal region 1p or multimodular molecular
characteristics could help, if yolk sac tumour is morpho-
logically considered [24].
As additional possibility, metastasis from the gastro-
intestinal tract was excluded based on the clinical and
imaging studies including gastro- and colonoscopy and
control staging during follow-up. Hence, the primary site
as endometrial cancer could be confirmed.
The early recidive situation after 16 months and tumour
related death of the patient after 21 months emphasises
the aggressive course, given the fact that the only initial
risk factor of staging was lymphangiosis carcinomatosa.
Previous reports on intestinal differentiation in endomet-
rial cancer revealed heterogeneous tumour elements with
interspersed goblet cells [2]. However, the current tumour
completely mimicked a mucinous adenocarcinoma of the
colon, which are also typically found to be right-sided and
hypermutated (MSI high). This molecular status was un-
equivocally present in our case, with protein loss of MLH1
and PMS2 due to hypermethylation of the MLH1 promotor
and functional high microsatellite instability. Thus, the
tumour shared not only the morphology, but also the
essential genetics of this type of colon cancer.
To the best of our knowledge, this is the first case of a
sporadic MSI high endometrial cancer with intestinal
differentiation. Whether this special tumour type should
be graded according to the endometrial cancer system
(moderate grade) or the colon cancer system (low
grade) remains unclear.
The recent Cancer Genome Atlas suggests a genetically
driven taxonomy of endometrial cancer. This case pro-
vides evidence that the category of MSI high hypermu-
tated endometrial cancer might contain so far under
represented morphologically diverse cancer subtypes. Of
note, only endometrioid and serous carcinomas of the
uterine corpus were integrated in the TCGA series.
Within these pre-selected cases, little is known about the
frequency of intestinal differentiation [9], but this has been
reported to be less than 1% elsewhere [8]. Thus, the
TCGA platform should be expanded to rare tumour en-
tities like mucinous adenocarcinoma of the endometrium,
as in the present case. Additionally, the search for simila-
rities between carcinomas of the uterine corpus, the
ovaries and the breast performed within the TCGA project
[9] should include other links like gastro-intestinal diffe-
rentiation and similarities to colorectal cancer.
Conclusions
In conclusion, this case is an extreme example in which
genetics alone could harbour considerable overlap be-
tween morphologically completely different cancer sub-
types, like this case of an MSI high intestinally
differentiated mucinous adenocarcinoma of the endomet-
rium in comparison with a conventional sporadic MSI
endometrioid adenocarcinoma. Thus, thorough genotype
and phenotype matching for studies in endometrial cancer
is essential. As presented above, the WHO classification
did not foresee an intestinal differentiated endometrial
adenocarcinoma. However, reports of such carcinomas
reach back more than 30 years [1] and might be con-
nected to certain premalignant conditions [4, 13]. The link
to MSI-genetics and a possible aggressive course warrant
its notification as a separate rare variant of mucinous
endometrium carcinoma.
Additional file
Additional file 1: Figure S1. Additional negative immunohistochemical
markers, p16 (A), AFP (B), Glypican3 (C) and SALL4 (D). (TIF 6136 kb)
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